Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 3/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 6/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.37 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25131888 | 0.83 | LMNA (0.45) | — | |
| SCHEMBL23607127 | 0.79 | PIM1 (0.44) | PIM1GRM4PARP1PIM3PRKCI | |
| SCHEMBL23606955 | 0.75 | KDM4E (0.36) | PRKCI | |
| SCHEMBL23607123 | 0.72 | PRKCA (0.48) | PIM1PIM3EGLN2FTOGRM5 | |
| SCHEMBL23607128 | 0.70 | PIM1 (0.46) | PIM1PIM3EGLN2FTO | |
| SCHEMBL23607121 | 0.68 | ATR (0.51) | PIM1PRKCI | |
| SCHEMBL25131885 | 0.67 | KDM4E (0.52) | PIM1GRM4PIM3PRKCI | |
| SCHEMBL30218613 | 0.67 | HTR2A (0.50) | PIM1PIM3CSF1RHTR2AHTR2C | |
| SCHEMBL13201028 | 0.67 | ATR (0.61) | PIM1GRM4CSF1RRETPDGFRB | |
| SCHEMBL23607118 | 0.67 | PIM1 (0.49) | PIM1PIM3PRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230103415-A1 | SMARCA INHIBITORS AND USES THEREOF | SMARCC1, SMARCE1, SMARCA1 | PIM1 1216/4885GRM4 4720/4885PARP1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.